Please assess the completion status of the following clinical trial:

Trial Title: Zomig - Treatment of Acute Migraine Headache in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent by parent or legal guardian, and written assent provided by patient prior to any study specific procedures.~* Established diagnosis of migraine.~* History of a minimum of 2 migraine attacks (moderately or severely disabling)per month.~Exclusion Criteria:~* Any medical condition that may put the patient at increased risk with exposure to zolmitriptan or that may interfere with the safety or efficacy assessments.~* A history of basilar, ophthalmoplegic, or hemiplegic migraine headache or any potentially serious neurological condition that is associated with headache.~* Have had an unacceptable adverse experience following previous use of any 5HT1B/1D agonist drug.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): ZOMIG 0.5 mg
- 3 (Type: EXPERIMENTAL): ZOMIG 2.5 mg
- 4 (Type: EXPERIMENTAL): ZOMIG 5.0 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).